PATENT CLAIM ANALYSIS

Application Number: 15756824
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Provided are a monoclonal antibody specific for BQ323636.1, and its use for prediction of tamoxifen resistance in breast cancer patients.

Claim (Index 18):
A method of determining whether a tamoxifen-treated subject is at risk of cancer relapse, or at risk for metastasis, comprising:\n (a) obtaining a tumor sample from the tamoxifen-treated subject; (b) determining in the sample a level of expression for a splice variant of NCOR2, wherein the splice variant is characterized by an exon 11 deletion during mRNA splicing resulting in an early translation stop codon and truncated protein wherein said determining the level of expression comprises using the antibody or antibody fragment of  claim 1 ; and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of the splice variant of NCOR2, with respect to the control, indicates that the tamoxifen-treated subject is at risk of cancer relapse or is at risk for metastasis.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 1.04762
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14429657', '10591199', '13568145', '13177523', '12825057']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7053853261427988
- 35 USC 102 Novelty (BERT): 0.5155382832137075
- Combined Prediction Score: 0.6864006218498897
- Mean Citation Score: 266.799774
- Max Citation Score: 274.01337
- Similarity Product: 161.19652604156082

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test